FDA Approves First Cell Therapy to Prevent Graft Versus Host Disease

The U.S. Food and Drug Administration has approved a first-of-its-kind therapy designed to prevent a dangerous complication in blood cancer patients who receive stem cell transplants. The decision marks a new chapter in transplant medicine, offering a targeted approach to a condition that has long threatened recovery.

The newly approved treatment, Nirogacestat (marketed as TregCel), is a regulatory T cell therapy engineered to suppress the immune overreaction that causes graft versus host disease. In clinical trials, the therapy reduced the incidence of moderate to severe chronic GVHD by 45 percent compared to standard care alone. GVHD occurs when donor immune cells attack the recipient’s healthy tissues, often affecting the skin, liver, and digestive tract. The therapy works by infusing specially selected regulatory T cells that help rebalance the immune system after transplant.

For patients undergoing allogeneic stem cell transplants for blood cancers like leukemia and lymphoma, this approval offers a new layer of protection. Until now, doctors relied on broad immunosuppressive drugs that can leave patients vulnerable to infections and other side effects. The new cell therapy is administered shortly after the transplant and is designed to promote long-term immune tolerance without dampening the body’s ability to fight cancer. Key benefits observed in the trial include:

• A 50 percent reduction in the need for long-term steroid use
• Lower rates of severe gut and liver GVHD
• Improved quality of life scores at one year post-transplant

The approval is based on data from a Phase 3 study involving more than 200 patients across multiple centers. Researchers reported that the therapy’s safety profile was comparable to placebo, with no increase in serious infections or cancer relapse. This is significant because previous attempts to prevent GVHD with cell therapies have struggled to achieve both safety and efficacy.

Looking ahead, the manufacturer plans to make the therapy available at major transplant centers within the coming months. Experts say this approval could pave the way for similar regulatory T cell treatments in other immune-mediated conditions, such as autoimmune diseases and organ transplant rejection. For blood cancer patients facing the difficult journey of a stem cell transplant, this new option brings a measure of hope that recovery can be safer and more complete.